New horizons for uncommon mutations in non-small cell lung cancer: <i>BRAF</i>, <i>KRAS</i>, <i>RET</i>, <i>MET</i>, <i>NTRK</i>, <i>HER2</i>
M.E. Olmedo, Raquel Cervera, Luis Cabezón‐Gutiérrez, Y. Lage, E. Corral de la Fuente, Ana Gómez Rueda, Xabier Mielgo-Rubio, Juan Carlos Trujillo-Reyes, Felipe Couñago
Abstract
all with frequencies greater than 1%. Lung cancers harbouring these genome changes can potentially be treated with agents approved for other indications or under clinical development. This review updates the therapeutic arsenal that especially targets those genes.
Topics & Concepts
ROS1KRASMedicineTargeted therapyCancer researchLung cancerAdenocarcinomaTyrosine kinaseOncologyMutationProtein-Tyrosine KinasesCancerGeneInternal medicineColorectal cancerBiologyGeneticsReceptorLung Cancer Treatments and MutationsCancer therapeutics and mechanismsColorectal Cancer Treatments and Studies